Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardiology Exam > Hyperlipidemia > Flashcards

Hyperlipidemia Flashcards

1
Q

chylomicrons - apolipoproteins, origin, and cargo

A

*apolipoproteins: Apo-B48, Apo-C-II, and Apo-E
*origin: small intestine → lymphatics
*cargo: triglycerides > cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

VLDL - apolipoproteins, origin, and cargo

A

*apolipoproteins: Apo-B100, Apo-C-II, Apo-E
*origin: liver
*cargo: triglycerides > cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

IDL - apolipoproteins, origin, and cargo

A

*apolipoproteins: Apo-B100, Apo-C-II, Apo-E
*origin: liver (more so a remnant of VLDL after it unloads some of its triglycerides)
*cargo: triglycerides/cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

LDL - apolipoproteins, origin, and cargo

A

*apolipoproteins: Apo-B100
*origin: liver
*cargo: cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

HDL - apolipoproteins, origin, and cargo

A

*apolipoproteins: Apo-A-1, Apo-C-II, Apo-E
*origin: liver
*cargo: cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

apolipoprotein A-1 (Apo A-I)

A

*structural protein for HDL
*activates LCAT enzyme

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

apolipoprotein B-48 (Apo-B48)

A

*structural protein for chlyomicrons

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

apolipoprotein B-100 (Apo-B100)

A

*structural protein for VLDL, IDL, LDL
*binds LDL receptor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

apolipoprotein C-II (Apo C-II)

A

*co-factor for LPL (lipoprotein lipase)
*Apo C-II enables LPL to unload triglycerides to tissues that need it for energy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

apolipoprotein E (Apo-E)

A

*ligand for binding to LDL receptor & LDL-like receptors
*helps particles get back to the liver to be broken down and remade into VLDL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

lipoprotein lipase (LPL)

A

*AN ENZYME THAT PRODUCES HYDROLYSIS IN LOW-DENISTY LIPOPROTEINS TO TURN THEM INTO GLYCEROL TO BE RELEASED IN THE MUSCLE
*expressed on endothelial cells in the heart, muscle, and adipose tissue
*has dual functions of triglyceride hydrolase and ligand/bridging factor for receptor-mediated lipoprotein uptake
*LPL isozymes are regulated differently depending on the tissue:
-the form that is in adipocytes is activated by insulin
-the form that is in muscle & myocardium is activated by glucagon & adrenaline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

exogenous cholesterol pathway (how we absorb & use dietary fats, lipids, and cholesterol)

A

*dietary fats are absorbed from the intestines & packaged into chylomicrons, which enter the circulation through the thoracic duct
*chylomicrons help to deliver triglycerides to tissues for energy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

lifecycle of chylomicrons

A
  1. dietary fats are absorbed in the small intestine and packaged into chylomicrons (Apo-B48 is attached)
  2. HDL in the bloodstream donates Apo-E and Apo-CII to the chylomicron
  3. mature chylomicrons travel through circulation and deposit triglycerides to muscles & adipose tissue to use for energy
  4. after delivering a significant amount of triglycerides, the chylomicron remnant returns to the liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

how do chylomicrons deliver triglycerides to muscle, myocardium, and adipose tissue?

A
  1. when one of these tissues is in need of energy, it expresses lipoprotein lipase (LPL) on its endothelial cells
  2. chylomicrons have Apo C-II, which interacts with the LPL receptors
  3. this interaction allows the chylomicrons to donate triglycerides to that tissue
  4. once the chylomicron has used up its reserve of Apo C-II, the chylomicron remnant uses Apo-E to return to the liver
  5. the chylomicron remnant is repackaged in the liver as VLDL
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

endogenous cholesterol pathway (how the liver packages lipids & cholesterol)

A

*liver produces VLDL, which delivers triglycerides to tissues
*as triglycerides are delivered to tissues, the particles get much smaller
*when the particle contains almost all cholesterol and few little triglyceride, it has become an LDL particle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

VLDL (Apo-B100) lifecycle

A
  1. tissues in need of energy express lipoprotein lipase (LPL) on their surface
  2. VLDL particles have Apo C-II, which interacts with LPL receptors
  3. this interaction allows VLDL particles to donate triglycerides to that tissue
  4. as the VLDL particle donates triglycerides, it becomes IDL
  5. IDL continues to donate triglycerides until it has used up its Apo C-II and no more triglycerides are left to donate
  6. at this point, the particle is LDL (contains only cholesterol & only has Apo B100)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

LDL receptor - overview

A

*LDL particle binds to LDL-receptor → receptor-mediated endocytosis (brings the LDL particle into the cell)
*inside the cell, endosomes combine and break down the lipid particles
*the receptor itself is recycled and returns to the cell surface, where it can bind another LDL particle

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

LDL receptor & PCSK-9

A

*if the cell does not need any more cholesterol, it produces & secretes PCSK-9
*PCSK-9 binds to the cell’s LDL receptors
*when the LDL particles bind to the PCSK-9-bound LDL receptors, they are brought into the cell via receptor-mediated endocytosis (like normal)
*however, the LDL receptors are then BROKEN DOWN (not recycled to the cell surface) so that there are no more LDL receptors on the cell surface

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

classical LDL receptor

A

*located on cell membranes of most tissues in the body, but the MAJORITY ARE FOUND IN THE LIVER
*binds apolipoprotein B-100 and Apo-E
*Apo-E binds LDL receptors with 20x affinity than Apo-B100
*therefore, it is more difficult for the LDL particles (which only have Apo-B100) to return to the liver compared to VLDL and IDL particles (which also have Apo-E)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

LDL-related protein-1 (LRP-1)

A

*acts as a scavenger receptor for remnant lipid particles
*binds Apo-E
*located in liver & nervous system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

reverse cholesterol transport (how free cholesterol finds its way back to the liver) - detailed

A
  1. HDL has Apo-A1, which activates the enzyme LCAT
  2. LCAT (lecithin-cholesterol acyltransferase) CONVERTS FREE CHOLESTEROL INTO CHOLESTERYL ESTER (a more hydrophobic form of cholesterol), which is then sequestered into the core of a lipoprotein particle, particularly HDL
  3. CETP (cholesteryl ester transfer protein) facilitates transport of cholesteryl esters & triglycerides between lipoproteins:
    -CETP enables HDL to give its cholesterol to lipoproteins that will go back to the liver (VLDL, IDL)
    -this enables HDL to remain in the periphery & scavenge more free cholesterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

reverse cholesterol transport (SIMPLE)

A
  1. HDL uses Apo-A1 to activate LCAT
  2. LCAT converts free cholesterol into cholesteryl ester
  3. HDL takes up the free cholesterol
  4. CETP (activated by LCAT) transfers cholesterol from HDL to VLDL and IDL
  5. VLDL & IDL return the cholesterol to the liver, while HDL remains in the periphery to scavenge for more free cholesterol
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

inhibition of HMG-CoA reductase (part of the cholesterol synthesis pathway)

A

results in:
1. a build-up of HMG-CoA (the substrate of the enzyme)
AND
2. a decrease in mevalonic acid (the product of the enzyme)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

hyperlipidemia - defined

A

*an increase in lipids in the blood
*hypercholesterolemia is a type of hyperlipidemia, but not all hyperlipidemias have increased LDL cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

causes of hyperlipidemia

A

*diet
*hypothyroidism
*nephrotic syndrome
*anorexia nervosa
*obstructive liver disease
*obesity
*diabetes mellitus
*pregnancy
*acute hepatitis
*SLE
*AIDS (protease inhibitors)

26
Q

Friedewald Equation for measuring LDL levels

A

*LDL = (total cholesterol - 0.2) x (triglycerides - HDL)
*LDL is not directly measured, but rather it is calculated
*note - cannot calculate LDL if triglycerides are > 400 mg/dl

27
Q

appearances of various increased lipoproteins in serum

A

*increased chylomicrons → creamy top layer
*increased LDL → clear
*increased VLDL/IDL → turbid

28
Q

type I hyperlipoproteinemia (familial hyperchylomicronemia)

A

*defects can be any of the following:
-lipoprotein lipase (LPL) deficiency
-familial Apo-CII deficiency
-circulating inhibitor of LPL

*increased particle = CHYLOMICRONS
*lab finding = increased triglycerides
*look out for pancreatitis!

29
Q

type I hyperlipoproteinemia (familial hyperchylomicronemia) - pathophysiology

A

*by inhibiting LPL, the chylomicron is unable to unload its triglyceride-rich content
*the VLDL which is made also cannot unload its triglycerides
*result = INCREASED CHYLOMICRONS & INCREASED TRIGLYCERIDES

30
Q

type IIa hyperlipoproteinemia (familial hypercholesterolemia)

A

*defect: defective LDL receptor
*increased particle = LDL
*lab findings = increased LDL, normal triglycerides

31
Q

type IIa hyperlipoproteinemia (familial hypercholesterolemia) - pathophysiology

A

*by having a defective LDL receptor, LDL builds up
*note that VLDL and IDL do not build up because hepatic lipase converts them to LDL

32
Q

dermatologic manifestations of hypercholesterolemia (type IIa hyperlipoproteinemia)

A

*xanthelasmas
*tendinous xanthomas
*corneal arcus

33
Q

xanthelesmas

A

*plaques or nodules composed of lipid-laden histiocytes in the EYELIDS
*associated with FAMILIAL HYPERCHOLESTEROLEMIA (type IIa hyperlipoproteinemia)

34
Q

tendinous xanthomas

A

*lipid deposits in tendons, especially Achilles tendon & finger extensors
*associated with FAMILIAL HYPERCHOLESTEROLEMIA (type IIa hyperlipoproteinemia)

35
Q

corneal arcus

A

*lipid deposits in corneas
*common in older adults (arcus senilis) but appears earlier in life with hypercholesterolemia
*associated with FAMILIAL HYPERCHOLESTEROLEMIA (type IIa hyperlipoproteinemia)

36
Q

type IIb hyperlipoproteinemia (familial combined hypercholesterolemia / hyperlipidemia)

A

*defect: defective/inhibited LDL receptor WITH increased apolipoprotein B100 production
*increased particles = LDL and VLDL
*lab findings = increased LDL and increased triglycerides

37
Q

type IIb hyperlipoproteinemia (familial combined hypercholesterolemia / hyperlipidemia) - pathophysiology

A

*by having a defective LDL receptor & increased Apo-B100, the VLDL, IDL, and LDL all build up
*VLDL/IDL build up because hepatic lipase is overwhelmed and can’t keep up in converting them to LDL

38
Q

type III hyperlipoproteinemia (familial dysbetalipoproteinemia)

A

*defect: defective apolipoprotein E related to larger particles
*increased particles = IDL, VLDL, and chylomicrons
*lab findings = increased triglycerides, increased total cholesterol

39
Q

dermatologic manifestations of dysbetalipoproteinemia (type III hyperlipoproteinemia)

A

*tubo-eruptive xanthomas
*palmar xanthomas

40
Q

tubo-eruptive xanthomas

A

*reddish bunos that appear suddenly over elbows, forearms, trunk, legs, extensor digitorum tendons, or buttocks
*associated with FAMILIAL DYSBETALIPOPROTEINEMIA (type III hyperlipoproteinemia)

41
Q

palmar xanthomas

A

*soft yellow plaques/nodules containing deposits of lipoproteins on the creases of the PALMS
*associated with FAMILIAL DYSBETALIPOPROTEINEMIA (type III hyperlipoproteinemia)

42
Q

type IV hyperlipoproteinemia (familial hyperlipidemia)

A

*defect: decreased removal of VLDL/excess VLDL production
*increased particle = VLDL
*lab finding = increased triglycerides

43
Q

type V hyperlipoproteinemia (familial hypertriglyceridemia)

A

*defect: increased VLDL production & decreased LPL activity
*increased particles = VLDL & chylomicrons
*lab findings = increased triglycerides
*look out for pancreatitis!

44
Q

apolipoprotein B48 defects

A

*if impairs production of chylomicrons, then leads to fat/cholesterol absorption problems:
-steatorrhea
-failure to thrive
-muscle wasting
-neurological issues/coordination
-fat soluble vitamin deficiencies

45
Q

apolipoprotein B100 defects

A

*if significant impairment of B100’s ability to bind LDL receptor, then may mimic familial hypercholesterolemia with high levels of LDL

46
Q

CETP (cholesterol ester transfer protein) defects

A

*rare mutations leading to reduced function of CETP have been linked to accelerated atherosclerosis
*a CETP inhibitor (Ancetropib) causes substantial increase in HDL and modest decline in LDL
*trans fats increase CETP activity

47
Q

LCAT (lecithin-cholesterol acyltransferase) defects

A

*impairment of LCAT leads to cholesterol deposits in the corneas, kidney, and other tissues and organs
*decreased LCAT concentration and activity are associated with decreased HDL levels but not with increased atherosclerosis

48
Q

LDL levels and risk of MI/CAD

A

*LOWER LDL levels are BETTER
*increasing LDL levels are associated with increased risk for MI and CAD

49
Q

LDL particle size & risk of atherosclerosis

A

*among individuals with the same LDL levels, the number of LDL particles and the size vary
*SMALLER LDL PARTICLES are associated with MORE ATHEROSCLEROSIS (it is easier for these particles to enter the arterial lining following injury)

50
Q

HDL levels & risk of MI

A

*individuals with high LDL PLUS LOW HDL are at the highest risk of developing an MI

51
Q

lipoprotein(a)

A

*sits on the surface of the LDL particle
*associated with a significantly INCREASED risk of atherosclerosis and coronary artery disease
*Lp(a) contributes to the process of atherogenesis: because of its structural similarity to plasminogen & tPA, competitive inhibition leads to reduced fibrinolysis
*must be very aggressive in lowering LDL

52
Q

statins - site of action

A

*competitive inhibition of HMG-CoA REDUCTASE in the liver (part of the cholesterol synthesis pathway)
*2 groups: hydrophilic and lipophilic

53
Q

effects of statins on LDL receptors & plasma LDL levels

A

*statins inhibit cholesterol synthesis → liver perceives a deficiency and expresses MORE LDL RECEPTORS to obtain cholesterol
*by increasing LDL receptors, LDL binds to the receptors and goes into the liver → LOWER PLASMA LEVELS OF LDL CHOLESTEROL

54
Q

atorvastatin

A

*example of LIPOPHILIC statin

55
Q

rosuvastatin

A

*example of HYDROPHILIC statin

56
Q

pleiotropic effects of statins

A

*increased platelet function
*decreased coagulation
*decreased inflammation
*decreased free radicals
*increased endothelial function
*increased collagen
*DECREASED LDL
*INCREASED HDL

57
Q

PCSK-9 inhibitors - MOA

A

*inhibition of PSCK-9 → LDL receptors return to the cell surface, rather than being degraded by lysosomes
*hence, LDL receptors increase → LDL levels DECREASE
*example = evolocumab

58
Q

bempedoic acid - MOA

A

*a first-in-class small molecular inhibitor of ATP-citrate lyase (which produces acetyl-CoA)

59
Q

non-pharmacologic considerations to lower lipids: DIETARY FAT/CHOLESTEROL

A

*monounsaturated fats: lowers LDL, raises HDL
*polyunsaturated fats: lowers LDL, raises HDL
*saturated fats: raises both LDL and HDL
*trans fats: raises LDL

60
Q

non-pharmacologic considerations to lower lipids: EXERCISE

A

*exercise is one of the few ways to RAISE HDL

Cardiology Exam (52 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions